[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07307833":3,"trial-entities:NCT07307833":80,"trial-summary:NCT07307833":85},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":20,"study_type":21,"primary_purpose":16,"phases":22,"enrollment_info":23,"interventions":26,"primary_outcomes":35,"secondary_outcomes":47,"sex":48,"minimum_age":49,"maximum_age":16,"healthy_volunteers":14,"eligibility_criteria":50,"std_ages":57,"locations":60,"central_contacts":70,"overall_officials":71,"references":75,"see_also_links":76},"NCT07307833","MC250709","Impact of Immunotherapy on Vestibular Function, The Mayo Clinic Arizona Experience","ENROLLING_BY_INVITATION","2029-10-31","2026-06","2026-06-16","2025-10-31","Mayo Clinic","OTHER",false,"This study evaluates the impact of immunotherapy on balance in patients receiving immunotherapy as part of their standard of care.",null,[18,19],"Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm",[],"OBSERVATIONAL",[],{"count":24,"type":25},50,"ESTIMATED",[27],{"type":13,"name":28,"description":29,"armGroupLabels":30,"otherNames":32},"Non-Interventional Study","Non-interventional study",[31],"Observational",[33,34],"Non-Interventional Observational Study","Noninterventional (Observational) Study",[36,40,44],{"measure":37,"description":38,"timeFrame":39},"Change in clinically significant vestibulopathy - vestibular function","Assessed using standard vestibular function testing. Results will be aggregated to determine overall vestibular function. Results from baseline (prior to initiating immunotherapy) will be compared to results at 3, 6, and 12 months.","Baseline, 3 months, 6 months, 12 months",{"measure":41,"description":42,"timeFrame":43},"Change in clinically significant vestibulopathy - hearing level","Assessed using Pure Tone Audiometry, a standard hearing test. Any change from baseline (prior to initiating immunotherapy) to 12 months will be reported.","Baseline,12 months",{"measure":45,"description":46,"timeFrame":39},"Oscillopsia Severity Questionnaire (OSQ)","The OSQ consists of 9 questions to assess visual environment sensation (episodes of oscillopsia). Questions are answered on a 5-point scale: always, often, sometimes, seldom, never. The OSQ is scored by calculating a mean item score, which results in a total score ranging from 1 to 5. A score of 3 or higher indicates moderate to extreme oscillopsia severity.",[],"ALL","18 Years",{"inclusion":51,"exclusion":54,"raw_text":56},[52,53],"At least 18 years of age at screening","Patients who will be initiating single agent immunotherapy with pembrolizumab, cemiplimab, nivolumab, atezolizumab, or dual therapy with (Ipilimumab\u002FNivolumab or Nivolumab\u002FRelatlimab)",[55],"Concurrent chemotherapy","Inclusion Criteria:\n\n* At least 18 years of age at screening\n* Patients who will be initiating single agent immunotherapy with pembrolizumab, cemiplimab, nivolumab, atezolizumab, or dual therapy with (Ipilimumab\u002FNivolumab or Nivolumab\u002FRelatlimab)\n\nExclusion Criteria:\n\n* Concurrent chemotherapy",[58,59],"ADULT","OLDER_ADULT",[61],{"facility":62,"city":63,"state":64,"zip":65,"country":66,"geoPoint":67},"Mayo Clinic in Arizona","Scottsdale","Arizona","85259","United States",{"lat":68,"lon":69},33.50921,-111.89903,[],[72],{"name":73,"affiliation":12,"role":74},"Carrlene B. Donald, PA-C, MS","PRINCIPAL_INVESTIGATOR",[],[77],{"label":78,"url":79},"Mayo Clinic Clinical Trials","https:\u002F\u002Fwww.mayo.edu\u002Fresearch\u002Fclinical-trials",{"nct_id":4,"conditions":81,"biomarkers":84},[82,83],"Hematologic Neoplasm","Solid Neoplasm",[],{"nct_id":4,"found":14,"summary":16,"prompt_version":16}]